EGFR and non-small cell lung carcinoma: However, an in vitro study showed that the growth of NSCLC cell lines harboring exon 19 deletion or L858R mutation were almost equally inhibited by equivalent concentrations of gefitinib, and the degree of EGFR phosphorylation [32].